<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286545</url>
  </required_header>
  <id_info>
    <org_study_id>EASIC 30505 registry</org_study_id>
    <nct_id>NCT01286545</nct_id>
  </id_info>
  <brief_title>European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study</brief_title>
  <acronym>EASIC registry</acronym>
  <official_title>European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rheumazentrum Ruhrgebiet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor Ortho Biotech Services, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rheumazentrum Ruhrgebiet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long term data on efficacy and safety of anti-TNF treatment with infliximab in patients with
      ankylosing spondylitis (AS) beyond 5 years is lacking. These data are important because
      patients with AS usually are younger and withdrawal of anti-TNF therapy in these patients
      almost always leads to a disease relapse. Furthermore it is still unclear whether long term
      anti-TNF treatment in AS patients can inhibit radiographic progression. Patients who
      participated in the EASIC and the DIKAS trial respectively who were treated with infliximab
      within these studies for 7 and 10 years respectively are followed up by using clinical
      outcome parameters every 6 months assessing efficacy and safety of long term treatment.
      Furthermore radiographs of the spine, if done for clinical indication, are analyzed. It is
      hypothesized that anti-TNF treatment with infliximab is effective and safe over a time period
      of 9 and 12 years respectively and that long term anti-TNF therapy may inhibit radiographic
      progression of the spine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ankylosing spondylitis (AS) is the most frequent subtype of spondyloarthritides (SpA)(Braun
      et al.Lancet 2007, 369:1379-90). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)
      is the cornerstone of the treatment of the disease and is widely used to suppress
      inflammation and ameliorate spinal pain (Zochling et al.:Ann Rheum Dis 2006, 65:442-52).
      There is evidence that antitumour necrosis factor (TNF) therapy is highly effective in SpA,
      especially in AS and psoriatic arthritis. Thus, TNF blockers may even be considered as first
      line treatment in a patient with active AS whose condition is not sufficiently controlled
      with NSAIDs in the case of axial disease, and sulfasalazine or methotrexate in the case of
      peripheral arthritis (Zochling et al.:Ann Rheum Dis 2006, 65:442-52). Long-term data on
      anti-TNF therapy in patients with AS are rather limited. Infliximab in a dosage of 5mg/kg was
      shown to be efficacious over 5 years, including a short period of withdrawal and
      readministration (Baraliakos et al.:Arthritis Res Ther 2005, 7: R439-44; Baraliakos et al.:J
      Rheumatol 2007, 34: 510-5; Braun J et al: Ann Rheum Dis 2008, 67: 340-5). In our EASIC study
      the investigators have also shown the efficacy and safety of infliximab treatment in patients
      with AS over 5 years. Long term data for the treatment of AS with etanercept has proven the
      efficacy as well (Dijkmans B et al.:J Rheumatol 2009, 36: 1256-64). But long term data for
      efficacy and safety of treatment with anti-TNF therapy beyond a time period of 5 years is
      lacking. These data on long term treatment are essential for several reasons. At first
      patients with AS are predominantly of younger age. When taking into account that withdrawal
      of anti-TNF therapy leads to disease relapse in a very high proportion of patients , anti-TNF
      therapy in AS patients is most often designed as a continuous therapy on a long term basis.
      The second reason for the need of long term data beyond 5 years is the ongoing debate whether
      anti-TNF agents have the potential to inhibit radiographic progression (Baraliakos X et
      al.:Ann Rheum Dis 2005, 64:1462-6; van der heijde D et al:Arthritis Rheum 2008, 58: 3063-70).
      Radiographic data on a larger cohort of patients treated with infliximab or other anti-TNF
      blockers for a long time period could contribute to answer this important question.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Ankylosing spondylitis, long term treatment with infliximab</arm_group_label>
    <description>Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ankylosing spondylitis who have completed:

          1. the trials ASSERT, EASIC and EASIC extension (overall 7 years)

          2. the trial DIKAS (overall 10 years)

        and who are still on infliximab or another anti-TNF agent wor who have terminated anti-TNF
        treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of ankylosing spondylitis according to the modified New York
             criteria

          -  Participation in the EASIC trial or participation in the DIKAS/TNF bei AS-trial

          -  Completion of the EASIC extension or the DIKAS trial

          -  Presence of written informed consent from the patient

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Braun, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Rheumazentrum Ruhrgebiet, Landgrafemstrasse 15, 44652 Herne, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jürgen Braun, Prof. Dr.</last_name>
    <phone>00492325592131</phone>
    <email>j.braun@rheumazentrum-ruhrgebiet.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Heldmann, Dr.</last_name>
    <phone>00492325592709</phone>
    <email>heldmann@rheumazentrum-ruhrgebiet.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Appelboom, Prof. Dr.</last_name>
      <email>tappelbo@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Thierry Appelboom, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis, Afdeling Rheumatologie</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filip van den Bosch, Dr.</last_name>
      <email>filip.vandenbosch@ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Kristel de Boeck, Mrs.</last_name>
      <email>kristel.deboeck@ugent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Filip van den Bosch, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kurt de Vlam, Dr.</last_name>
      <phone>003216332211</phone>
      <email>kurt.devlam@uz.kuleuven.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Jilke Beinsberger, Mrs.</last_name>
      <phone>003216332211</phone>
      <email>jilke.beinsberger@uz.leuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt de Vlam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Central Hospital, Division of Rheumatology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029HYKS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjatta Leirisalo-Repo, Prof. Dr.</last_name>
      <email>Marjatta.Leirisalo-Repo@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Arja Karto</last_name>
      <email>arja.karto@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Marjatta Leirisalo-Repo, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hopitalier Cochin</name>
      <address>
        <city>Boulogne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxime Breban, Prof. Dr.</last_name>
      <phone>0033149095672</phone>
      <email>maxime.breban@cch.ap-hop-paris.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire Ribet, Mrs.</last_name>
      <phone>0033149095672</phone>
      <email>claire.ribet@apr.ap-hop-paris.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Maxime Breban, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat R. Decartes, Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sami Kolta, Dr.</last_name>
      <phone>0033158412584</phone>
      <email>sami.kolta@cch.ap-hop-paris.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Ménagé, Mrs</last_name>
    </contact_backup>
    <investigator>
      <last_name>Maxime Dougados, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sami Kolta, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugen Feist, Dr.</last_name>
      <phone>004930450513133</phone>
      <email>eugen.feist@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Mattat, Mrs.</last_name>
      <phone>004930450513133</phone>
      <email>katrin.mattat@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerd Burmester, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugen Feist, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hildrun Haibel, Dr-</last_name>
      <phone>00493084454414</phone>
      <email>hildrun.haibel@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Renate Pauli, Mrs.</last_name>
      <phone>00493084452660</phone>
      <email>renate.pauli@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joachim Sieper, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hildrun Haibel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immanuel Krankenhaus Berlin Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Krause, Prof. Dr.</last_name>
      <phone>00493094792300</phone>
      <email>a.krause@immanuel.de</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Herz, Mrs.</last_name>
      <phone>00493094792300</phone>
      <email>C.Herz@immanuel.de</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Krause, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatologie Schlosspark-Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svitlana Dyachenko, Dr.</last_name>
      <phone>00493032641325</phone>
      <email>svitlana.dyachenko@schlosspark-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Rieke Alten, Dr.</last_name>
      <phone>00493032641325</phone>
      <email>rieke.alten@schlosspark-klinik.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rieke Alten, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svitlana Dyachenko, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Sörensen, Dr.</last_name>
      <phone>00493081810188</phone>
      <email>h.soerensen@rheuma-berlin.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Sander, Mrs.</last_name>
      <phone>00493081810188</phone>
      <email>p.sander@rheuma-berlin.com</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Sörensen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Düsseldorf, Universitätsklinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Schneider, Prof. Dr.</last_name>
      <phone>00492118117817</phone>
      <email>schneider@rheumanet.org</email>
    </contact>
    <contact_backup>
      <last_name>Elsbeth Richter, Mrs.</last_name>
      <phone>00492118117817</phone>
      <email>Elsbeth.Richter@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Schneider, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Immunologie und Rheumatologie der MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Rihl, Dr.</last_name>
      <phone>00495115325252</phone>
      <email>Rihl.Markus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Scheiwe, Mrs.</last_name>
      <phone>00495115325252</phone>
      <email>Rht-Studienambulanz@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>R.E. Schmidt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Rihl, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Heldmann</last_name>
      <phone>00492325592112</phone>
      <email>heldmann@rheumazentrum-ruhrgebiet.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Braun, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Heldmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Rheumaeinheit</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Witt, Dr.</last_name>
      <phone>00498951603455</phone>
      <email>Matthias.Witt@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Christine Strasser, Mrs.</last_name>
      <phone>00498951603455</phone>
      <email>Christine.Strasser@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Witt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irene vander Horst-Bruinsma, Dr.</last_name>
      <phone>0031204443432</phone>
      <email>I.E.vanderHorst@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Silvy Weismann, Mrs.</last_name>
      <phone>0031204443432</phone>
      <email>S.Weismann@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Irene van der Horst-Bruinsma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid van Tubergen, Dr.</last_name>
      <phone>0031433875026</phone>
      <email>a.van.tubergen@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Janine Geusen, Mrs.</last_name>
      <phone>0031433875026</phone>
      <email>j.geusen@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid van Tubergen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cambridge /Clin Med</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hill Gaston, Prof. Dr.</last_name>
      <phone>00441233330161</phone>
      <email>jshg2@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Dominique R Roy, Mrs.</last_name>
      <phone>00441233330161</phone>
      <email>dr314@medschl.cam.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Hill Gaston, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9N2</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura C Coates, Dr.</last_name>
      <phone>004411339224848</phone>
      <email>L.C.Coates@leeds.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>David Pickles, Mr.</last_name>
      <phone>004411339224848</phone>
      <email>David.Pickles@leedsth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Emery, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura C Coates, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007 Apr 21;369(9570):1379-90. Review.</citation>
    <PMID>17448825</PMID>
  </reference>
  <reference>
    <citation>Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J; 'ASsessment in AS' international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006 Apr;65(4):442-52. Epub 2005 Aug 26.</citation>
    <PMID>16126791</PMID>
  </reference>
  <reference>
    <citation>Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439-44. Epub 2005 Feb 21. Erratum in: Arthritis Res Ther. 2005;7(3):113. Zink, Angela [added];Alten, Rieke [added]; Burmester, Gerd [added]; Gromnica-Ihle, Erika [added]; Kellner, Herbert [added]; Schneider, Matthias [added]; Sörensen, Helmut [added]; Zeidler, Henning [added]; Rudwaleit, Martin [added].</citation>
    <PMID>15899030</PMID>
  </reference>
  <reference>
    <citation>Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007 Mar;34(3):510-5. Epub 2007 Feb 1.</citation>
    <PMID>17299842</PMID>
  </reference>
  <reference>
    <citation>Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008 Mar;67(3):340-5. Epub 2007 Oct 29.</citation>
    <PMID>17967831</PMID>
  </reference>
  <reference>
    <citation>Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol. 2009 Jun;36(6):1256-64. doi: 10.3899/jrheum.081033. Epub 2009 May 1. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.</citation>
    <PMID>19411393</PMID>
  </reference>
  <reference>
    <citation>Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005 Oct;64(10):1462-6. Epub 2005 Mar 18.</citation>
    <PMID>15778240</PMID>
  </reference>
  <reference>
    <citation>van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008 Oct;58(10):3063-70. doi: 10.1002/art.23901.</citation>
    <PMID>18821688</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>January 27, 2011</last_update_submitted>
  <last_update_submitted_qc>January 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>Braun, Jürgen, Prof. Dr. med</name_title>
    <organization>Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne</organization>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Radiographic progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

